National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedKamineni M, Ötleş Meng E, Oh J
Prospective evaluation of data-driven models to predict daily risk of Clostridioides difficile infection at 2 large academic health centers.
The purpose of this prospective study was to assess a data-driven approach for Clostridioides difficile infection (CDI) risk prediction that had previously demonstrated a high performance in retrospective evaluations at 2 large academic health centers. The final retrospective cohort included 18,030 admissions (138 CDI cases) at Massachusetts General Hospital (MGH) and 25,341admissions (158 CDI cases) at Michigan Medicine. The prospective cohort included 13,712 admissions (119 CDI cases) at MGH and 26,864 admissions (190 CDI cases) at MM. At MGH, the model achieved area under the receiver operator characteristic curve (AUROC). AUROCs of 0.744 in the retrospective cohort and 0.748 in the prospective cohort. At MM, the model achieved AUROCs of 0.778 in the retrospective cohort and 0.767 in the prospective cohort. The AUROCs for predicting CDI risk on both retrospective and prospective cohorts were similar each month and did not exhibit significant monthly variation throughout either assessment period.
AHRQ-funded; HS027431.
Citation: Kamineni M, Ötleş Meng E, Oh J .
Prospective evaluation of data-driven models to predict daily risk of Clostridioides difficile infection at 2 large academic health centers.
Infect Control Hosp Epidemiol 2023 Jul; 44(7):1163-66. doi: 10.1017/ice.2022.218..
Keywords: Clostridium difficile Infections, Healthcare-Associated Infections (HAIs), Risk
Morgan DJ, Dubberke ER, Hink T
The impact of universal glove and gown use on Clostridioides difficile acquisition: a cluster-randomized trial.
This article described a secondary analysis of a cluster-randomized trial in medical and surgical intensive care units (ICUs) in 20 US hospitals to assess whether universal gown and glove use decreases Clostridioides difficile infection. ICUs were randomized to standard practice for glove and gown use versus all healthcare workers required to wear gloves and gowns for all patient contact or when entering a patient room. The results showed no significant difference in the rate of toxigenic C. difficile with universal gown and glove use.
AHRQ-funded; HS025456.
Citation: Morgan DJ, Dubberke ER, Hink T .
The impact of universal glove and gown use on Clostridioides difficile acquisition: a cluster-randomized trial.
Clin Infect Dis 2023 Feb 8; 76(3):e1202-e07. doi: 10.1093/cid/ciac519..
Keywords: Clostridium difficile Infections, Healthcare-Associated Infections (HAIs), Prevention
Patel P, Deshpande A, Yu PC
Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia.
The purpose of this study was to explore the relationships between the antibiotic regimens of empiric therapy with a respiratory fluoroquinolone or cephalosporin plus macrolide combination and the development of hospital-onset Clostridioides difficile infection (CDI). The researchers used data from 638 United States hospitals and included adults admitted with pneumonia and discharged from July 2010 through June 2015 with a pneumonia diagnosis code who received 3 or more days of either antibiotic regimen. The study sample included 58,060 patients treated with either cephalosporin plus macrolide (36,796 patients) or a fluoroquinolone alone (21,264 patients). 0.35% of patients who received cephalosporin plus macrolide and 0.31% who received a fluoroquinolone developed CDI, making CDI risks similar for fluoroquinolones versus cephalosporin plus macrolide.
AHRQ-funded; HS024277.
Citation: Patel P, Deshpande A, Yu PC .
Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia.
Infect Control Hosp Epidemiol 2023 Jan; 44(1):47-54. doi: 10.1017/ice.2022.60..
Keywords: Pneumonia, Clostridium difficile Infections, Healthcare-Associated Infections (HAIs), Medication, Infectious Diseases, Community-Acquired Infections